CenterBook Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

CenterBook Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.66M	Buy	15,486 +10,426	+206%	+$7.1M	0.47%	43
2026 Q1	$3.91M	Sell	5,060 -25,186	-83%	-$19.3M	0.21%	123
2025 Q4	$23.3M	Sell	30,246 -26,977	-47%	-$18.3M	1.14%	13
2025 Q3	$32.2M	Buy	57,223 +5,632	+11%	+$3.18M	1.59%	6
2025 Q2	$27.1M	Buy	51,591 +45,877	+803%	+$25.6M	1.5%	9
2025 Q1	$3.62M	Sell	5,714 -10,270	-64%	-$7.06M	0.23%	119
2024 Q4	$11.4M	Sell	15,984 -7,784	-33%	-$6.53M	0.68%	29
2024 Q3	$25M	Buy	23,768 +19,050	+404%	+$21.2M	1.54%	7
2024 Q2	$4.96M	Buy	+4,718	New	+$4.57M	0.31%	118

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

CenterBook Partners's REGN Position: Q2 2026 in Review

CenterBook Partners increased its Regeneron Pharmaceuticals (REGN) stake by 206% in Q2 2026, buying an estimated $7.1M and bringing the position to 15,486 shares worth $9.66M. The position accounts for 0.47% of the portfolio, ranked #43.

CenterBook Partners first reported a position in REGN in Q2 2024 and has held it in 9 quarters since. The position peaked at $32.2M in Q3 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

CenterBook Partners held 15,486 shares of Regeneron Pharmaceuticals worth $9.66M as of Q2 2026.
CenterBook Partners bought 10,426 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $7.1M.
Regeneron Pharmaceuticals made up 0.47% of CenterBook Partners's portfolio in Q2 2026, its #43 holding.
CenterBook Partners first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
CenterBook Partners's Regeneron Pharmaceuticals position peaked at $32.2M in Q3 2025.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.